AUTL
Autolus TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
The best supported bull argument is that Autolus is now pairing a real commercial base with maintained 2026 AUCATZYL guidance. The 10-K showed $74.3 million of 2025 net product revenue and a U.K.
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
Commercial concentration risk: AUCATZYL is the only approved product and remains the main revenue driver, with no EU sales anticipated in 2026 per the 10-K [#10-K-2026-03-27].
Momentum
94
Value
41
Sentiment
54
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.60 · Bull $2.40 · Bear $0.80
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-29 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $8.27
Why
Momentum94 · Δ7d -
Value41 · Δ7d -0.1
Sentiment54 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
94
26% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
54
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade B. Momentum 94.2 / Value 41.1 / Sentiment 54.2
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$383.26M
Beta
1.98
Shares Out
266.16M
P/E (TTM) · Derived
-1.3
P/S (TTM)
9.68
P/FCF (TTM) · Derived
-1.33
Rev YoY
+191.4%
EPS YoY
+1.9%
Gross Margin
-17.4%
Op Margin
-535.8%
Net Debt
$49.37M
Current Ratio
5.76
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology